Centessa Pharmaceuticals PLCNASDAQ:CNTA
- LAST PRICE15.7350
- TODAY'S CHANGE (%)-0.1450 (-0.9131%)
- Bid / Lots15.7200/ 1
- Ask / Lots15.7500/ 1
- Open / Previous Close15.9700 / 15.8800
- Day Range
- 52 Week Range
- Volume184,618
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNTA |
|---|---|---|
| 09:32 ET | 1574 | 15.8252 |
| 09:34 ET | 1100 | 15.57 |
| 09:41 ET | 100 | 16.15 |
| 09:48 ET | 1439 | 16.14 |
| 09:52 ET | 100 | 16.055 |
| 09:54 ET | 300 | 15.99 |
| 09:57 ET | 200 | 15.955 |
| 10:08 ET | 678 | 15.97 |
| 10:10 ET | 200 | 16.04 |
| 10:14 ET | 100 | 15.8835 |
| 10:15 ET | 200 | 16.035 |
| 10:21 ET | 700 | 15.9418 |
| 10:26 ET | 351 | 15.975 |
| 10:32 ET | 100 | 15.94 |
| 10:33 ET | 100 | 16.04 |
| 10:35 ET | 100 | 16.0025 |
| 10:37 ET | 100 | 16.05 |
| 10:42 ET | 100 | 16.02 |
| 10:46 ET | 100 | 16.01 |
| 10:48 ET | 100 | 16.02 |
| 10:51 ET | 900 | 16.07 |
| 10:53 ET | 200 | 16.015 |
| 10:57 ET | 619 | 16.045 |
| 11:00 ET | 2273 | 16.07 |
| 11:02 ET | 300 | 16.15 |
| 11:11 ET | 1951 | 16.245 |
| 11:13 ET | 370 | 16.24 |
| 11:15 ET | 600 | 16.195 |
| 11:18 ET | 600 | 16.175 |
| 11:22 ET | 1600 | 16.155 |
| 11:24 ET | 1400 | 16.19 |
| 11:27 ET | 100 | 16.13 |
| 11:31 ET | 700 | 16.145 |
| 11:33 ET | 200 | 16.15 |
| 11:38 ET | 100 | 16.12 |
| 11:40 ET | 100 | 16.145 |
| 11:42 ET | 100 | 16.145 |
| 11:44 ET | 200 | 16.17 |
| 11:45 ET | 200 | 16.175 |
| 11:47 ET | 100 | 16.155 |
| 11:51 ET | 100 | 16.115 |
| 11:58 ET | 728 | 16.06 |
| 12:00 ET | 1200 | 16.055 |
| 12:02 ET | 1566 | 16.08 |
| 12:03 ET | 100 | 16.05 |
| 12:05 ET | 1327 | 15.945 |
| 12:12 ET | 100 | 15.93 |
| 12:14 ET | 100 | 15.93 |
| 12:16 ET | 794 | 15.91 |
| 12:18 ET | 219 | 15.905 |
| 12:20 ET | 387 | 15.905 |
| 12:21 ET | 369 | 15.89 |
| 12:25 ET | 300 | 15.77 |
| 12:27 ET | 300 | 15.765 |
| 12:30 ET | 700 | 15.72 |
| 12:32 ET | 400 | 15.72 |
| 12:34 ET | 200 | 15.72 |
| 12:36 ET | 100 | 15.76 |
| 12:38 ET | 500 | 15.775 |
| 12:39 ET | 300 | 15.775 |
| 12:41 ET | 200 | 15.785 |
| 12:43 ET | 400 | 15.75 |
| 12:45 ET | 500 | 15.75 |
| 12:48 ET | 200 | 15.72 |
| 12:52 ET | 1153 | 15.735 |
| 12:56 ET | 400 | 15.71 |
| 12:57 ET | 300 | 15.7 |
| 12:59 ET | 300 | 15.695 |
| 01:01 ET | 400 | 15.705 |
| 01:03 ET | 1300 | 15.7 |
| 01:06 ET | 1100 | 15.67 |
| 01:08 ET | 545 | 15.67 |
| 01:10 ET | 1220 | 15.585 |
| 01:12 ET | 960 | 15.66 |
| 01:14 ET | 1845 | 15.7 |
| 01:15 ET | 548 | 15.705 |
| 01:17 ET | 400 | 15.65 |
| 01:19 ET | 661 | 15.66 |
| 01:21 ET | 500 | 15.72 |
| 01:24 ET | 600 | 15.73 |
| 01:26 ET | 600 | 15.76 |
| 01:28 ET | 500 | 15.745 |
| 01:30 ET | 300 | 15.72 |
| 01:32 ET | 400 | 15.69 |
| 01:33 ET | 600 | 15.72 |
| 01:37 ET | 1501 | 15.69 |
| 01:39 ET | 500 | 15.73 |
| 01:42 ET | 100 | 15.78 |
| 01:44 ET | 1200 | 15.745 |
| 01:46 ET | 22400 | 15.77 |
| 01:48 ET | 45140 | 15.89 |
| 01:50 ET | 700 | 15.9 |
| 01:51 ET | 300 | 15.85 |
| 01:53 ET | 937 | 15.8 |
| 01:55 ET | 600 | 15.8 |
| 01:57 ET | 400 | 15.8 |
| 02:00 ET | 600 | 15.795 |
| 02:02 ET | 700 | 15.7707 |
| 02:04 ET | 900 | 15.76 |
| 02:06 ET | 1100 | 15.71 |
| 02:08 ET | 400 | 15.75 |
| 02:09 ET | 1008 | 15.71 |
| 02:11 ET | 600 | 15.75 |
| 02:13 ET | 783 | 15.755 |
| 02:15 ET | 400 | 15.745 |
| 02:18 ET | 408 | 15.74 |
| 02:20 ET | 400 | 15.745 |
| 02:22 ET | 500 | 15.75 |
| 02:24 ET | 729 | 15.77 |
| 02:26 ET | 200 | 15.755 |
| 02:27 ET | 1061 | 15.755 |
| 02:29 ET | 513 | 15.75 |
| 02:31 ET | 1629 | 15.705 |
| 02:33 ET | 300 | 15.69 |
| 02:36 ET | 300 | 15.7 |
| 02:38 ET | 500 | 15.7 |
| 02:40 ET | 700 | 15.685 |
| 02:42 ET | 800 | 15.725 |
| 02:44 ET | 400 | 15.755 |
| 02:45 ET | 500 | 15.73 |
| 02:47 ET | 600 | 15.71 |
| 02:49 ET | 880 | 15.71 |
| 02:51 ET | 400 | 15.74 |
| 02:54 ET | 500 | 15.72 |
| 02:56 ET | 1210 | 15.73 |
| 02:58 ET | 916 | 15.75 |
| 03:00 ET | 600 | 15.725 |
| 03:02 ET | 752 | 15.71 |
| 03:03 ET | 400 | 15.705 |
| 03:05 ET | 600 | 15.7 |
| 03:07 ET | 300 | 15.725 |
| 03:09 ET | 300 | 15.755 |
| 03:12 ET | 500 | 15.78 |
| 03:14 ET | 600 | 15.735 |
| 03:16 ET | 400 | 15.755 |
| 03:18 ET | 500 | 15.745 |
| 03:20 ET | 400 | 15.7 |
| 03:21 ET | 600 | 15.715 |
| 03:23 ET | 600 | 15.74 |
| 03:25 ET | 1400 | 15.755 |
| 03:27 ET | 600 | 15.805 |
| 03:30 ET | 600 | 15.815 |
| 03:32 ET | 1063 | 15.725 |
| 03:34 ET | 500 | 15.735 |
Sep 26, 2024
Sep 19, 2024
DJ Centessa Pharmaceuticals Raised to Overweight From Equal-Weight by Morgan Stanley, from 6:22PM ET on Thursday Sep 19, 2024 by Dow Jones
6:22PM ET on Thursday Sep 19, 2024 by Dow JonesDJ Centessa Pharmaceuticals Initiated at Buy by B. Riley Securities, from 7:35AM ET on Thursday Sep 19, 2024 by Dow Jones
7:35AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 16, 2024
DJ Centessa Pharmaceuticals Is Maintained at Outperform by BMO Capital, from 9:02AM ET on Monday Sep 16, 2024 by Dow Jones
9:02AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
DJ Centessa Pharmaceuticals Shares Rise After $225M Public Offering, from 10:55AM ET on Friday Sep 13, 2024 by Dow Jones
10:55AM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Centessa Pharmaceuticals PLC | 2.0B | -10.1x | --- |
Celldex Therapeutics Inc | 2.0B | -11.2x | --- |
Akero Therapeutics Inc | 1.9B | -8.3x | --- |
Neumora Therapeutics Inc | 2.2B | -8.8x | --- |
Soleno Therapeutics Inc | 1.9B | -20.3x | --- |
Vera Therapeutics Inc | 2.2B | -18.6x | --- |
Company Information
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Contact Information
- Headquarters
- 3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Francesco de Rubertis
- Chief Executive Officer, Director
- Saurabh Saha
- Chief Financial Officer
- John Crowley
- Chief People Officer
- Karen Anderson
- Executive Vice President and Chairman of Development
- Antoine Yver
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 128.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-1.56 |
Book Value | $2.39 |
P/E Ratio | -10.1x |
Price/Sales (TTM) | 297.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,268.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
